Steadvar — News without the noise

Privacy · Terms · About

© 2026 Steadvar. All rights reserved.

Justice Department Moves to Reclassify Marijuana to Lower-Risk Category

PoliticsHealth4/23/2026
Share

Similar Articles

Trump Signs Executive Order to Fast-Track Psychedelic Drug Research

PoliticsHealth4/20/2026

Justice Department Reauthorizes Firing Squads and Single-Drug Executions

CrimePolitics4/24/2026

FDA Grants Fast-Track Review to Three Psychedelic Drugs for Mental Health Conditions

HealthPolitics4/24/2026

Justice Department Proposes Rule to Review Ethics Complaints Against Federal Prosecutors

Politics4/25/2026

FDA Commissioner Marty Makary Removed After Pressure Over Vape Approvals

PoliticsHealth18h ago

The Justice Department has ordered an expedited hearing to reclassify FDA-approved and state-licensed marijuana from a Schedule I to a Schedule III drug. This change would ease research barriers but does not legalize the drug or affect current prison sentences. The hearing to evaluate the broader change is set to begin on June 29.

Facts First

  • The Justice Department (DOJ) will hold an expedited hearing to reclassify marijuana from Schedule I to Schedule III.
  • The change applies to FDA-approved and state-licensed marijuana, easing Drug Enforcement Administration (DEA) barriers to research.
  • Reclassification would not legalize marijuana or affect sentences for those incarcerated for possession.
  • The hearing to evaluate the broader change is scheduled to begin on June 29.
  • The move follows an executive order signed by President Trump in December directing the attorney general to continue the push to change federal restrictions.

What Happened

Acting Attorney General Todd Blanche ordered the immediate reclassification of FDA-approved and state-licensed marijuana from a Schedule I to a Schedule III drug. The Justice Department (DOJ) announced it will hold a new, expedited hearing to evaluate this broader change to the drug's status under federal law, which is scheduled to begin on June 29. This action follows an executive order signed by President Trump in December directing the attorney general to continue efforts to change federal restrictions on marijuana.

Why this Matters to You

If you or someone you know uses marijuana for medical purposes in a state where it is legal, this reclassification could eventually lead to more research into its potential benefits and risks. For researchers, the change eases significant federal barriers to studying the drug. However, the change does not immediately legalize marijuana at the federal level, and it will not affect the sentences of individuals currently incarcerated for possession.

What's Next

The Justice Department's expedited hearing on the reclassification is set to begin on June 29. The outcome of this hearing will determine the final status of marijuana under federal law. If the reclassification is finalized, marijuana would be categorized alongside drugs like ketamine and steroids, which are considered to have a lower potential for abuse and a currently accepted medical use.

Perspectives

“
Government Officials contend that reclassification will facilitate "more targeted, rigorous research into marijuana's safety and efficacy," ultimately expanding patient access and improving medical decision-making.
“
Medical Researchers suggest that reclassification will streamline the study of medicinal applications and help secure support from influential figures within the research community.